Prognostic impact of chromogranin A in patients with acute heart failure

Background: Chromogranin A (CgA) levels have been reported to predict mortality in patients with heart failure. However, information on the prognostic value and clinical availability of CgA is limited. We compared the prognostic value of CgA to that of previously proven natriuretic peptide biomarker...

Full description

Saved in:
Bibliographic Details
Published inJournal of yeungnam medical science Vol. 38; no. 4; pp. 337 - 343
Main Authors Kim, Hong Nyun, Yang, Dong Heon, Park, Bo Eun, Park, Yoon Jung, Kim, Hyeon Jeong, Jang, Se Yong, Bae, Myung Hwan, Lee, Jang Hoon, Park, Hun Sik, Cho, Yongkeun, Chae, Shung Chull
Format Journal Article
LanguageEnglish
Published Korea (South) Yeungnam University College of Medicine 01.10.2021
영남대학교 의과대학
Subjects
Online AccessGet full text
ISSN2384-0293
2384-0293
2799-8010
DOI10.12701/yujm.2020.00843

Cover

More Information
Summary:Background: Chromogranin A (CgA) levels have been reported to predict mortality in patients with heart failure. However, information on the prognostic value and clinical availability of CgA is limited. We compared the prognostic value of CgA to that of previously proven natriuretic peptide biomarkers in patients with acute heart failure.Methods: We retrospectively evaluated 272 patients (mean age, 68.5±15.6 years; 62.9% male) who underwent CgA test in the acute stage of heart failure hospitalization between June 2017 and June 2018. The median follow-up period was 348 days. Prognosis was assessed using the composite events of 1-year death and heart failure hospitalization.Results: In-hospital mortality rate during index admission was 7.0% (n=19). During the 1-year follow-up, a composite event rate was observed in 12.1% (n=33) of the patients. The areas under the receiver-operating characteristic curves for predicting 1-year adverse events were 0.737 and 0.697 for N-terminal pro-B-type natriuretic peptide (NT-proBNP) and CgA, respectively. During follow-up, patients with high CgA levels (>158 pmol/L) had worse outcomes than those with low CgA levels (≤158 pmol/L) (85.2% vs. 58.6%, p<0.001). When stratifying the patients into four subgroups based on CgA and NT-proBNP levels, patients with high NT-proBNP and high CgA had the worst outcome. CgA had an incremental prognostic value when added to the combination of NT-proBNP and clinically relevant risk factors.Conclusion: The prognostic power of CgA was comparable to that of NT-proBNP in patients with acute heart failure. The combination of CgA and NT-proBNP can improve prognosis prediction in these patients.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
http://www.e-yujm.org/journal/view.php?doi=10.12701/yujm.2020.00843
ISSN:2384-0293
2384-0293
2799-8010
DOI:10.12701/yujm.2020.00843